<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651948</url>
  </required_header>
  <id_info>
    <org_study_id>6253</org_study_id>
    <nct_id>NCT02651948</nct_id>
  </id_info>
  <brief_title>Transperineal, MRI-guided, Prostate Biopsy</brief_title>
  <official_title>Transperineal, MRI-guided, Prostate Biopsy: First Step to Focal Treatment of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary purpose:

      Complications and rehospitalizations after transperineal prostate biopsy MRI-guided are
      reduced than transrectal prostate biopsies.

      Secondary purposes:

        -  Patients tolerance after transperineal prostate biopsy MRI-guided is better than after
           transrectal prostate biopsies.

        -  Core of transperineal prostate biopsies are better than core of transrectal prostate
           biopsies

        -  Study of correlation between radiologic images and anatomopathologic result

        -  Description of needle track during the procedure

        -  Description of real time template saturation prostate biopsy

        -  Comparison of transperineal prostate biopsy relevance according to EBM

        -  Comparison of 1.5T MRI and 3T MRI for prostate cancer detection
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Collection of complications and rehospitalizations by using questionnaire</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Transperineal prostate biopsy (TPB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transperineal prostate biopsy MRI-guided</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transrectal prostate biopsy (TRB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transrectal prostate biopsy echo-guided</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transperineal, MRI-guided, prostate biopsy</intervention_name>
    <arm_group_label>Transrectal prostate biopsy (TRB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transrectal prostate biopsy (TRB):</intervention_name>
    <arm_group_label>Transperineal prostate biopsy (TPB)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Men

          -  40 to 80 years' old

          -  Affiliation to French social health system

          -  Signed consent

          -  Prostate cancer suspicion based on prostate specific antigen (PSA) or digital rectal
             exam WITH abnormal MRI (Prostate Imaging Reporting and Data System score 3) AND
             negative transrectal prostate biopsies

          -  Patient treated by active surveillance for a low risk prostate cancer (T1c or T2a,
             Gleason = 6, PSA &lt; 10)

        Exclusion criteria:

          -  Gleason &gt; 6 prostate cancer

          -  Metastatic prostate cancer

          -  Contraindication to MRI

          -  Contraindication to general anesthesia

          -  Non-reversible hemostasis trouble

          -  Inability to give consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lang Hervé, MD</last_name>
    <email>herve.lang@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tricard Thibault</last_name>
    <email>thibault.tricard@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'urologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Lang, MD</last_name>
      <email>herve.lang@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

